Financial Highlights & Revenue Break Up

Financial Highlights & Revenue Break Up

30,000

25,000

20,000

15,000

10,000

5,000

0

16,918

FY 18

22,792

FY 19

25,986

FY 20

Revenue

30%

25%

20%

15%

10%

5%

0%

16.5%

FY 18

16.8%

FY 19

20.2%

FY 20

EBITDA %

6,000

5,000

4,000

3,000

2,000

1,000

0

2,784

FY 18

3,840

FY 19

5,253

FY 20

EBITDA

4,200

3,500

2,800

2,100

1,400

7,00

0

1,326

FY 18

2,364

FY 19

3,355

FY 20

PAT

18%

15%

12%

9%

6%

3%

0%

7.8%

FY 18

10.4%

FY 19

12.9%

FY 20

PAT%

24,000

20,000

16,000

12,000

8,000

4,000

0

13,042

FY 18

15,295

FY 19

18,437

FY 20

Networth

24,000

20,000

16,000

12,000

8,000

4,000

0

11,996

FY 18

14,729

FY 19

18,752

FY 20

Gross Block

Break-up of Consolidated Revenue as per Geography

FY'20 (Rs. in Mn)
13,879

53%

5,055

19%

2,100

8%

3,795

15%

1,157

4%

North America
Europe
India
Latin America
Row

Break-up of Consolidated Revenue as per Business Segment

FY'20 (Rs. in Mn)
13,602

52%

8,170

31%

4,214

16%

API
PFI
FD

Break-up of Consolidated Revenue as per Molecule

FY'20 (Rs. in Mn)
7,487

29%

6,011

23%

6,397

25%

733

3%

1,374

5%

3,985

15%

Paracetamol
Metformin
Guaifenesin
Ibuprofen
Methocarbamol
Others

Break-up of Consolidated Revenue as per Business Segment

FY'20 (Rs. in Mn)
13,602

52%

8,170

31%

4,214

16%

API
PFI
FD